Neurorehabilitation News

The FDA has approved an expanded indication of Boston Scientific’s spinal cord stimulation system that treats painful diabetic peripheral neuropathy, a complication of diabetes that often affects the lower extremities.

Presence of cytokine proteins in those with neuromyelitis optica spectrum disorder was linked to disease activity, which was lessened after treatment with inebilizumab, according to a presentation from ECTRIMS 2023.

In those with traumatic brain injury, patterns of two blood-based biomarkers were similar between the sexes, with significantly higher concentrations of one in male patients compared with female patients, according to research from Nature.

Oragenics Inc. and Odyssey Health Inc. have announced an agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies.

A Bay Area pharmaceutical firm has announced positive data from a phase 3 clinical trial evaluating Chenodal tablets to treat adults with cerebrotendinous xanthomatosis, an autosomal, recessive, progressive genetic disorder.

A Manhattan-based biopharmaceutical firm has announced positive topline data from its phase 2 trial of a novel formulation of intranasal racemic ketamine for acute suicidal ideation and behavior in adults with major depressive disorder.

Brain-based biomarkers of likely drug response were associated with a greater mean reduction in reported PTSD symptoms in a study of patients treated with ALTO-100.

Regeneron Pharmaceuticals Inc. and Intellia Therapeutics Inc. have announced an expanded research collaboration intended to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases.

Use of artificial intelligence triage software led to a significant reduction in 30- and 120-day all-cause mortality for those with intracranial hemorrhage compared with those treated without the algorithm, according to research.

A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental health disorders.